Is it safe to switch between efavirenz and nevirapine in the event of toxicity?

Lancet Infectious Diseases

Volumn 7, Issue 11, 2007, Pages 733-738

  Mehta, Ushma ^a   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

BLISTER; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DESQUAMATION; DRUG CROSS REACTIVITY; DRUG ERUPTION; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA MULTIFORME; ERYTHRODERMA; ETHNICITY; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LIVER TOXICITY; MACULOPAPULAR RASH; MENTAL DISEASE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SEX; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

BENZOXAZINES; CROSS REACTIONS; DRUG ERUPTIONS; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 35348995999     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(07)70262-1     Document Type: Review

References (50)

1. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision (2002), World Health Organization, Geneva. http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf (accessed Sept 14, 2007).
2. van Leth F., Phanuphak P., Ruxrungtham K., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 (2004) 1253-1263
3. Adkins J., and Noble S. Efavirenz. Drugs 56 (1998) 1055-1064
4. Drugs.com. Sustiva product information. http://www.drugs.com/pro/sustiva.html (accessed Sept 28, 2007).
5. Soriano V., Dona C., Barreiro P., and González-Lahoz J. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?. AIDS 14 (2000) 1672-1673
6. Zapor M., Cozza K., Wynn G., Wortmann G., and Armstrong S. Antiretrovirals, part II: focus on non-protease inhibitor antiretrovirals (NRTIS, NNRTIs and fusion inhibitors). Psychosomatics 45 (2004) 524-535
7. Arranz J.C., Gorgolas M., Estrada V., and Garcia-Diaz J. Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors. HIV Med 5 (2004) 128-129
8. Kappelhoff B., Huitema A., and Beijnen J. Should non-nucleoside reverse transcriptase inhibitors be combined?. Drugs R D 6 (2005) 61-69
9. Mazhude C., Jones S., Murad S., Taylor C., and Easterbrook P. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 16 (2002) 1566-1568
10. Pirmohamed M., and Park B. HIV and drug allergy. Curr Opin Allergy Clin Immunol 1 (2001) 311-316
11. Gutiérrez F., Navarro A., Padilla S., et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41 (2005) 1648-1653
12. Marzolini C., Telenti A., Decosterd L., Greub G., Biollaz J., and Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15 (2001) 71-75
13. Gangar M., Arias G., O'Brien J., and Kemper C. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother 34 (2000) 839-842
14. Ananworanich J., Siangphoe U., Chan J., et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 19 (2005) 185-192
15. Perez-Molina J. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicentre prospective study in 1033 HIV-infected patients. HIV Clin Trials 3 (2002) 279-286
16. Shenton J., Popovic M., Chen J., Masson M., and Uetrecht J. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female brown Norway rat. Chem Res Toxicol 18 (2005) 1799-1813
17. Van Leth F., Andrews S., Grinsztejn B., et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 19 (2005) 463-471
18. Fagot J., Mockenhaupt M., Bouwes-Bavinck J., Naldi L., Viboud C., and Roujeau J. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15 (2001) 1843-1848
19. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, October, 2006. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed Sept 14, 2007).
20. Bourezane Y., Salard D., Hoen B., Vandel S., Drobacheff C., and Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 27 (1998) 1321-1322
21. Bossi P., Colin D., Bricaire F., and Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 30 (2000) 227-228
22. Ho T., Wong K., Chan K., and Lee S. High incidence of nevirapine-associated rash in HIV-infected Chinese. AIDS 12 (1998) 2082-2083
23. Martin A., Nolan D., James I., et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T cell counts. AIDS 19 (2005) 97-99
24. Liechty C., Solberg P., Mwima G., Were W., Weidle P., and Mermin J. Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS 34 (2005) 405-407
25. Barreiro P., Soriano V., Casas E., et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 14 (2000) 2153-2157
26. Montaner J., Cahn P., Zala C., et al. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 33 (2003) 41-46
27. Antinori A., Baldini F., Girardi E., et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 15 (2001) 1579-1581
28. Sanne I., Mommeja-Marin H., Hinkle J., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 191 (2005) 825-829
29. Abrescia N., D'Abbraccio M., Figoni M., et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus coinfection. J Antimicrob Chemother 50 (2002) 763-765
30. Baylor M., and Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 35 (2004) 538-539
31. Martin-Carbonero L., Núñez M., Gonzalez-Lahoz J., and Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 4 (2003) 115-120
32. Núñez M., and Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanism and management. Drug Saf 28 (2005) 53-66
33. Sulkowski M., Thomas D., Mehta S., Chaisson R., and Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35 (2002) 182-189
34. De Requena D.G., Nunez M., Jimenez-Nacher I., and Soriano V. Liver toxicity caused by nevirapine. AIDS 16 (2002) 290-291
35. Martinez E., Blanco J., Arnaiz J., et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15 (2001) 1261-1268
36. Kappelhoff B., van Leth F., Robinson P., et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir Ther 10 (2005) 489-498
37. Dieterich D., Robinson P., Love J., and Stern J. Drug-induced liver injury associated with the use of non-nucleoside reverse transcriptase inhibitors. Clin Infect Dis 38 suppl 2 (2004) S80-S89
38. Haas D. Will pharmacogenomic discoveries improve HIV therapeutics?. Top HIV Med 13 (2005) 90-95
39. Freercks R., Mehta U., Stead D., and Meintjes G. Haemolytic anaemia associated with efavirenz. AIDS 20 (2006) 1212-1213
40. Bundow D., Rosoff L., and Aboulafia D. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain. AIDS Read 11 (2001) 577-580
41. Podzamczer D., Consiglio E., Ferrer E., and Gudiol F. Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction to nevirapine. AIDS 14 (2000) 331-332
42. Torralba M., Neira M., Rubio R., et al. Evaluation of cutaneous cross-toxicity between efavirenz and nevirapine-containing regimens in clinical practice. Antivir Ther 8 (2003) L82 (abstract 125).
43. Manosuthi W., Thongyen S., Chumpathat N., Muangchana K., and Sungkanuparph S. Incidence and risk factors of rash associated with efavirenz n HIV-infected patients with preceding nevirapine-associated rash. HIV Med 7 (2006) 378-382
44. Clarke S., Harrington P., Barry M., and Mulcahy F. The tolerability of efavirenz after nevirapine-related adverse events. Clin Infect Dis 31 (2000) 806-807
45. Hartmann M., Brust J., Schuster D., et al. Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz. Hautarzt 56 (2005) 847-853 (in German).
46. Roujeau J., and Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994) 1272-1285
47. Audicana M., Bernaola G., Urrutia I., et al. Allergic reactions to betalactams: studies in a group of patients allergic to penicillin and evaluation of cross-reactivity with cephalosporin. Allergy 49 (1994) 108-113
48. Novalbos A., Sastre J., Cuesta J., et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy 31 (2001) 438-443
49. Strom B., Schinnar R., Apter A., et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 349 (2003) 1628-1635
50. Apter A., Kinman J., Bilker W., et al. Is there cross-reactivity between penicillins and cephalosporins?. Am J Med 119 (2006) 354.e11-354.e19